Camlin Fine Sciences shares plunged to a 52-week low of ₹78.98 after reporting a consolidated net loss of ₹29.7 crore for Q2 FY2027. Operating margins contracted significantly to 0.45% due to rising input costs and freight expenses. To improve liquidity, the company has announced a ₹250 crore rights issue, as it struggles with working capital constraints and weak performance in its Aroma business.
Camlin Fine Sciences (CFS) witnessed a sharp sell-off on November 4, 2026, with its share price dropping to a 52-week low of ₹78.98. This negative market reaction followed the company's financial results for the second quarter of the 2027 fiscal year, which reflected significant operational stress and a decline in profitability.
The company reported a consolidated net loss of ₹29.7 crore for the quarter, widening from a loss of ₹14.95 crore in the same period last year. While revenue from operations showed a year-on-year growth of 9.1% to ₹4,914.65 million, this top-line improvement failed to translate into earnings. The most critical takeaway for investors was the collapse in operating margins, which plummeted to 0.45% from 7.91% in the corresponding quarter of the previous year. Management identified elevated raw material prices, high freight expenses, and inefficient working capital cycles as the primary drivers behind this sharp margin contraction.
In an effort to stabilize its financial position, the board of directors has approved a fundraising plan of up to ₹250 crore through a rights issue. This capital injection is designed to help the company address persistent liquidity issues, settle dues with creditors, and reduce its dependence on high-cost channel financing. For investors, the success of this fundraise is a key monitorable, as the company faces pressure to normalize its balance sheet and improve cash flow.
The business segments of Camlin Fine Sciences are currently experiencing diverging trends. The Blends division continues to show demand resilience, particularly in the food and pet food sectors. However, the Aroma business remains a major point of concern. This segment is currently battling pricing pressure, partly driven by an excess of cheaper inventory from Chinese competitors, and is undergoing a transition in its product lines. The impact of these segment-specific challenges has been a drag on overall performance.
Looking ahead, the company is targeting a financial turnaround by the fourth quarter of the fiscal year, with revenue projections aiming to exceed ₹600 crore. However, achieving these targets depends heavily on the company's ability to execute its plans, manage raw material costs effectively, and successfully complete the rights issue. Investors will likely track the progress of these initiatives in the coming quarters to see if the management can stabilize margins and restore operational efficiency in a volatile macro environment.